The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial - Takeaways - MDSpire

The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial

  • By

  • Alba Solera-Sanchez

  • Hayley Marriott

  • Stanley Windsor

  • Kim Straun

  • Marie A. Neu

  • Elias Dreismickenbecker

  • Francesca Lanfranconi

  • Linda Peli

  • Joachim Wiskemann

  • Nikolai Bauer

  • Filippo Spreafico

  • William Zardo

  • Tobias Baader

  • Peter Wright

  • Joerg Faber

  • Eila Watson

  • on behalf of the FORTEe Consortium

  • July 8, 2026

  • 0 min

Share

  • 1

    The FORTEe clinical trial utilized the Pixformance motion tracking device to enhance exercise interventions for children and young adults with cancer.

  • 2

    Ninety children aged 4–21 years participated in interviews, while 33 healthcare professionals completed an online survey regarding the technology.

  • 3

    Participants appreciated the device for its variety of exercises and real-time feedback, although some experienced technical issues with motion detection.

  • 4

    Healthcare professionals acknowledged the benefits of supervised exercise but noted challenges related to transport and offline use of the technology.

  • 5

    CAYA suggested incorporating gamification features like rewards and avatar customization to improve motivation and engagement with the exercise program.

Original Source(s)

The use of motion tracking technology to support an exercise intervention for children and young people with cancer: perspectives of users and healthcare professionals in the FORTEe trial

  • by Alba Solera-Sanchez, Hayley Marriott, Stanley Windsor, Kim Straun, Marie A. Neu, Elias Dreismickenbecker, Francesca Lanfranconi, Linda Peli, Joachim Wiskemann, Nikolai Bauer, Filippo Spreafico, William Zardo, Tobias Baader, Peter Wright, Joerg Faber, Eila Watson, on behalf of the FORTEe Consortium

  • July 8, 2026

Related Content

MemSAM-2.5D: overcoming volumetric discontinuity and boundary ambiguity for 3D liver tumor segmentation

Ectopic craniopharyngioma recurrence: a case report and literature review

The role of 18F-FDG PET/CT in identifying risk factors for ground-glass nodules in invasive lung adenocarcinoma